Printer Friendly

COMPARISON OF TROPONIN I WITH CK-MB AND ECG FOR PREDICTING CLINICALLY SIGNIFICANT MYOCARDIAL INJURY AFTER CORONARY ARTERY BYPASS GRAFTING.

Byline: Syed Shaheer Haider Bukhari, Rashad Siddiqi, Rehana Javaid, Jehan Essa and Rahmeen Pervaiz Khan

Keywords: Troponin I, CK-MB, CABG, Perioperative MI.

INTRODUCTION

The incidence of perioperative myocardial infarction (PMI) ranges from 7-15% after cardiac surgery affecting length of hospital stay (HLOS), incurred cost and more importantly reduced short term survival1-3. WHO included chest pain, cardiac specific biomarkers and new ECG changes as diagnosis of acute myocardial infarction (AMI) whereas 2007 Task Force of ESC/ACCF/AHA/WHF redefined PMI as elevated cardiac enzymes at five times upper limit of laboratory normal (ULN) within 72 hrs after surgery associated with new Q waves or ST changes or LBBB on ECG4. Various studies searched for "ideal" cardiac marker that would demonstrate absolute cardiac specificity, would not be present in blood without cardiac muscle damage and its concentration would rise rapidly after a heart attack and it would be inexpensive to test for and could be performed on automated instruments5. Those markers ranged from nonspecific AST, LDH and CK to more specific LD1, CK-MB, Myoglobin, Trop T and Trop I.

The dimer CK-MB level increases within 3-12 hrs of onset of chest pain, peaks within 24 hrs and returns to baseline after 48-72 hrs whereas Trop I has same initial rise but peaks at 24-48 hrs and returns to baseline over 5-14 days. Some trials have shown that cTnI and CK-MB to beat 96% and 52% respectively in identifying PMI6. In addition, it was also noted that patients who had elevated cTnI without AMI could have 10-fold increase in the odds of developing later cardiac complications including death and would benefit from invasive therapies7,8. In Intensive Care of our institution, we carry out quantitative CK-MB on POD 0-3 for CABG patients and direct our therapies accordingly. In this study, the positive predictive values of quantitative CK-MB and cTnI are compared in detecting PMI, risk of short term mortality and increased HLOS thereby directing early interventional therapies, reducing costs and subsequent validating Task Force's recommendations on Pakistani cardiac surgical population.

MATERIAL AND METHODS

This was a descriptive comparative study conducted on 122 patients, who underwent elective coronary artery bypass grafting (CABG) at operating theatres and subsequently followed in intensive care and high dependency units. With Institutional Review Board approval, written consent was obtained from each patient. During preoperative assessment, patient's demographics, EURO score noted, baseline ECG interpreted and blood samples taken for baseline quantitative nTnI and CK-MB if not taken already. Age over 20 years, ejection fraction above 20% and cardiopulmonary bypass with single aortic crossclamp technique were considered inclusive factors while redo CABG, HCT less than 25%, recent MI and concomitant valve procedures were excluded from the study. Sampled with consecutive non probability technique and selected by Armed forces nursing staff that were trained and informed about the inclusion and exclusion criteria.

Patients were assessed on 2007 Task Force of ESC/ACCF/AHA/WHF perioperative MI criteria. cTnI compared with CK-MB and ECG in predicting clinically significant PMI, short term morbidity/mortality and length of hospital stay (HLOS). For statistical analysis of demographic data, descriptive statistics (percentage, mean, median and mode) were taken. For comparison of groups, ANOVA was applied for continuous variables and chi square test was performed for categorical variables. A p-value <0.05 was taken as statistically significant.

Table-I: Demographics of study population.

Variable###Mean +- SD###Median

Age (years)###50.75 +- 7.49###52 (years)

Height (cms)###173.88 +- 9.65###176 cm

Weight (kgs)###78.84 +- 11.25###81 kg

Stay (days)###7.61 +- 4.08###6 (days)

Table-II: Statistical Comparison of clinically significant variables ( p<0.05).

Variables###PMI###ECG###Mortality###Inotropic###Prolong###HLOS###IABP###CRRT

###Support###Ventilation

Elevated###<0.001###<0.001###<0.001###<0.001###<0.001###<0.001###<0.001###0.79

cTnI

Elevated###<0.001###<0.001###<0.001###<0.001###<0.001###<0.001###<0.001###60%) with 8 (6.4%, p 0.001) patients had >6 days stay in significant CKMB group as compared to 6 (4.8%, p 0.001) patients for elevated cTnI. Perioperatively 10 (8%) patients had atrial fibrillation in elevated CKMB group as compared to 4 (3.3%) in elevated cTnI group.

Frequency of IABP and CRRT was 11 (8.8%, p 0.002) and 2 (1.6%) in elevated cTnI group as compared to 24 (19.2%, p 0.001) and 6 (4.8%, p 0.001) in elevated CKMB group respectively. In this study we also observed that sustained rise of either cTnI or CKMB for initial two days of surgery carried added morbidity/mortality. After two days, further per day enzymes measurements was of no significance and added cost burden to patients specially in decelerating trends. It was also observed that CKMB elevation was significantly predicted postoperative renal compromise with subsequent CRRT use. The statistical significances of this study is shown in table-II.

DISCUSSION

According to the findings of the present study, the incidence of PMI was 19.2% which is higher than internationally quoted values ranging from 7-15%1,2,3. This variation may be attributed to so called "Asiatic coronaries" (small caliber), differences in surgical techniques, perfusion strategies, myocardial protection and surgical selection criteria. In similar studies evaluating both enzymes in European population9,10 showed a low profile superiority of cTnI over CKMB but our study has shown an equivocal statistically significant relationship between elevated cTnI and CKMB in predicting PMI and consequently do-able supportive measures to steer morbidity/mortality pathway. It has been shown by various studies11-14 that cTnI and CKMB if combined with ECG, can effectively diagnose myocardial ischemia which is also shown in our study. However, isolated ECG changes carry little to no significance15.

Our study was unique in many ways. Firstly, it evaluated task force's recommendations on Pakistani population which has not been validated in any asian country. Secondly, it included many other factors such as prolong ventilation, inotropic support and use of CRRTwhich not only showed the added benefit in predicting required supportive measures but also assist in early start of therapies to prevent irremediable damage of vital organs16-18. Finally, one more surprising strength of our study was a statistical significant relationship between elevated CKMB levels with possibility of renal stunning and use of CRRT. The literature review has few non RCTs19,20 showing that the surges of CKMB and cTnI has positive correlation with renal dysfunction but none predicted the institution of renal therapies.

With numerous merits, our study has demerits too which can be rectified in future studies. Firstly, such study can be devised to make it a randomized controlled trial. Secondly, sample size can be increased to make it more representative of Pakistani population. Thirdly, inclusion of surgical techniques, perfusion strategies and surgical selection criteria can help lessen errors if any.

CONCLUSION

In conclusion, we are confident that cTnI or CKMB with ECG carry equal predictive power to detect clinically significant myocardial injury following CABG according to recommendations that CKMB carries additional association with renal dysfunction which needs to be evaluated further. It is also important to consider only one enzyme at a time according to ease and cost of laboratory procedures. However it is also being emphasized that isolated ECG changes for detection of PMI carry little significance if not supported by cardiac enzymes elevation and hemodynamic compensations.

ACKNOWLEDGEMENT

I would like to take this opportunity to express my gratitude to my supervisor Prof Col Rashad Siddiqi for incorporating various learning ways not only in academics but also personal. His versatility will always highlight a sense of sharp perfection for my future. He was the only source of containment for me in cardiothoracic anesthesia.

CONFLICT OF INTEREST

This study has no conflict of interest to be declared by any of its authors.

REFERENCES

1. Ramsay J, Shernan S, Fitch J, Finnegan P, Todaro T, Filloon T, et al. Increased creatine kinase MB level predicts postoperative mortality after cardiac surgery independent of new Q waves. J Thorac Cardiovasc Surg 2005; 129: 300-306.

2. Croal BL, Hillis GS, Gibson PH, Fazal MT, El-Shafei H, Gibson G, et al. Relationship between postoperative cardiac troponin I levels and outcome of cardiac surgery. Circulation 2006; 114: 1468-75.

3. Chen JC, Kaul P, Levy JH, Haverich A, Menasche P, Smith PK, et al. Myocardial infarction following coronary artery bypass graft surgery increases healthcare resource utilization. Crit Care Med 2007; 35: 1296-1301.

4. Thygesen K, Alpert JS, White HD, on behalf of the Joint ESC/ACCF/AHA/WHF. Task Force for the Redefinition of Myocardial Infarction. Eur Heart J 2007; 28: 2525-38.

5. Morrow DA. Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial. JAMA 2001; 286(19): p. 2405-12.

6. Muehlschlegel JD. Troponin is superior to electrocardiogram and creatinine kinase MB for predicting clinically significant myocardial injury after coronary artery bypass grafting. Eur Heart J 2009; 30: 1574-83.

7. Cannon CP. Invasive versus conservative strategies in unstable angina and non-Q-wave myocardial infarction following treatment with tirofiban: rationale and study design of the international TACTICS-TIMI 18 Trial. Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy. Thrombolysis In Myocardial Infarction. Am J Cardiol 1998; 82(6): 731-6.

8. Kontny F. Improving outcomes in acute coronary syndromes--the FRISC II trial. Clin Cardiol, 2001; 24(3 Suppl): I3-7.

9. Morrow DA. Cardiac troponin I for stratificationof early out-comes and the efficacy of enoxaparin in unstable angina: a TIMI-11B substudy. J Am Coll Cardiol 2000; 36(6): 1812-7.

10. Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, et al. ESC guidelines on management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. Rev EspCardiol 2009; 62(3): 293, e1-47.

11. Francis M. Rapid bedside whole blood cardiac specific troponin-T immunoassay for diagnosis of acute myocardial infarction. Am Heart J. 1995; 75(12): 842-5.

12. Alhashemi JA. Diagnostic accuracy of a bedside qualitative immunochromatographic test for acute myocardial infarction. Am J Emerg Med 2006; 24(2): 149-55.

13. Pollack CV Jr, Braunwald E. 2007 update to the ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: Implications for emergency department practice. Ann Emerg Med 2008; 51(5): 591-606.

14. Wu AH, Feng YJ, Contois JH, Pervaiz S. Comparison of myoglobin, creatine kinase-MB, and cardiac troponin I for diagnosis of acute myocardial infarction. Ann Clin Lab Sci 1996; 26(4): 291-300.

15. McQueen MJ, Holder D, El-Maraghi NR. Assessment of the accuracy of serial electrocardiograms in the diagnosis of myocardial infarction. Am Heart J 1983; 105(2): 258-61.

16. Nigam PK. Biochemical markers of myocardial injury. Indian J Clin Biochem 2007; 22(1): 10-7.

17. H. Metzler, M. Gries, P. Rehak, T. Lang, S. Fruhwald, W. Toller Perioperative myocardial cell injury: the role of troponins Br J Anaesth, 78 1997; pp. 386-390.

18. DA Morrow, CP Cannon, N Rifai. TACTICS-TIMI 18 Investigators. Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial JAMA 2001; 286: 2405-2412

19. FS Apple, AHB. Wu Myocardial infarction redefined: role of cardiac troponin testing Clin Chem 2001; 47: 337-39

20. Freda. Cardiac Troponins in Patients With Renal Insufficiency JACC 2002; 40(12): 2065-71.

21. Stolear JC, Georges B, Shita A, Verbeelen D. The predictive value of cardiac troponin T measurements in subjects on regular haemodialysis. Nephrol Dial Transplant 1999; 14: 1961-7.
COPYRIGHT 2019 Knowledge Bylanes
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Pakistan Armed Forces Medical Journal
Date:Feb 28, 2019
Words:2083
Previous Article:HYPER IMMUNOGLOBULIN E IGE SYNDROME (HIES) WITH PARTIAL T LYMPHOCYTES DEFICIENCY.
Next Article:TRANSCATHETER DEVICE CLOSURE OF PERIMEMBRANOUS VENTRICULAR SEPTAL DEFECT FROM RIGHT VENTRICULAR APPROACH WITHOUT ARTERIOVENOUS LOOP.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters